GlassScriptPhysician profile
Barton M Lewis
NPI 1811956535
$875.91
in general payments reported to CMS, 2019-2025
10 companies · $21.94 in 2025
The $21.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $14.91 · 2021: $118 · 2022: $186 · 2023: $206 · 2024: $182 · 2025: $21.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274.81 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $210.28 | 2021-2023 | |
| Amgen INC. | $123.72 | 2019-2024 | Repatha, Otezla |
| Abbott Laboratories | $104.76 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $55.11 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $45.82 | 2022 | |
| Astellas Pharma US INC | $20.03 | 2024 | Veozah |
| Boston Scientific Corporation | $17.36 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barton Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.